Tesamorelin in Endocrine Research

Tesamorelin is a 44-amino-acid synthetic analog of growth-hormone-releasing hormone. It differs from native GHRH by a single trans-3-hexenoic acid modification on the N-terminus, which protects the molecule from rapid enzymatic degradation. The result is a research peptide that activates the GHRH receptor with a half-life suitable for laboratory time scales rather than the minutes-long window of unmodified GHRH.

Why the modification matters

Native GHRH is degraded by dipeptidyl peptidase-4 (DPP-4) within minutes of entering serum. Without modification, GHRH is a difficult research peptide to work with because the dose-response window is narrow and short, and small variations in timing produce large variations in observed effect.

Tesamorelin's N-terminal hexenoic-acid modification slows DPP-4 cleavage substantially. The kinetic profile becomes workable: researchers can study the GHRH axis without their entire signal being lost to first-pass degradation.

Sequence and synthesis

Tesamorelin's full sequence is well-characterized in the peer-reviewed literature. Solid-phase synthesis of a 44-residue peptide demands attention to coupling efficiency at every position — a single skipped coupling produces a deletion peptide that may co-elute on HPLC. Identity confirmation by mass spectrometry and main-peak purity by HPLC are non-negotiable for research use, and REPRIME publishes both for every batch.

The 20 mg vial

Lyophilized at -20°C, 20 mg gives enough material for extended protocols. Reconstitute with sterile diluent immediately before use; do not store reconstituted solution for longer than the period specified on the COA. The HPLC report is updated per batch on the [product page](/shop/tesamorelin) and the [Certificates repository](/certificates).

Positioning

Tesamorelin is research-grade material for endocrine and growth-hormone-axis studies. REPRIME does not market it for any non-research application and does not provide dosage or protocol guidance.